Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Apexbio Technology LLC LY3200882 1898283-02-7 50mg
Supplier: Apexbio Technology LLC B845450
LY3200882 (CAS 1898283-02-7) is a small-molecule therapeutic currently being evaluated in preclinical and clinical oncology research Its mechanism of action involves modulation of signaling pathways relevant to tumor immune evasion potentially enhancing antitumor immune responses Present research focuses on clinical assessment of LY3200882 combined with pembrolizumab an immune checkpoint inhibitor in patients with advanced cancers (clinical trial NCT04158700) This investigation aims to clarify LY3200882 s immunomodulatory role and therapeutic potential in oncology
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?